Current research on Antithrombotics


MATRIX trial is still ongoing. We will publish soon the results of the randomization between bivalirudin and UFH at 1 month, and will finish the 12-month follow up by the end of this year.

We are in the preliminary phases of the TWILIGHT study, a multicenter RCT coordinated by the Mount Sinay Hospital, PI will be Roxana Tehran. An update will be posted soon.

Bivalirudin use-an update after the Matrix trial

This is the presentation I had at the CCIF meeting at Guiyang, China, April 2015.

Which is the current role of Bivalirudin in ACS patients, nowadays? Did the Matrix trial change the scenario, or created more confusion on the matter?

 

FinalBivalirudin presentation China